Jefferies Financial Group reissued their hold rating on shares of AstraZeneca (LON:AZN) in a report published on Friday. Jefferies Financial Group currently has a GBX 5,800 ($75.79) price target on the biopharmaceutical company’s stock.

AZN has been the topic of several other research reports. Barclays restated an overweight rating and issued a GBX 6,600 ($86.24) target price (up previously from GBX 6,500 ($84.93)) on shares of AstraZeneca in a report on Friday, August 10th. Deutsche Bank restated a buy rating and issued a GBX 6,000 ($78.40) target price (up previously from GBX 5,700 ($74.48)) on shares of AstraZeneca in a report on Friday, July 13th. Credit Suisse Group set a GBX 5,900 ($77.09) target price on shares of AstraZeneca and gave the stock a buy rating in a report on Friday, July 27th. Liberum Capital restated a hold rating on shares of AstraZeneca in a report on Friday, August 31st. Finally, JPMorgan Chase & Co. set a GBX 5,800 ($75.79) target price on shares of AstraZeneca and gave the stock a buy rating in a report on Friday, July 20th. Three analysts have rated the stock with a sell rating, seven have given a hold rating and thirteen have issued a buy rating to the company. The company currently has an average rating of Hold and an average price target of GBX 5,700.70 ($74.49).

Shares of AZN traded down GBX 70 ($0.91) on Friday, hitting GBX 5,546 ($72.47). 2,077,869 shares of the stock traded hands, compared to its average volume of 2,310,000. AstraZeneca has a one year low of GBX 4,260 ($55.66) and a one year high of GBX 5,520 ($72.13).

AstraZeneca Company Profile

AstraZeneca PLC discovers, develops, and commercializes prescription medicines for the treatment of oncology, cardiovascular and metabolic, respiratory, gastrointestinal, neuroscience, and infection diseases worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor2, Plendil, Seloken/Toprol-XL4, Tenormin5, and Zestril6 for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases.

Featured Story: What is insider trading?

Analyst Recommendations for AstraZeneca (LON:AZN)

Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.